Literature DB >> 1856127

Antimicrobial effects of lomefloxacin in vitro.

S T Chambers1, B A Peddie, R A Robson, E J Begg, D R Boswell.   

Abstract

The MIC of lomefloxacin was determined for 554 isolates from the urinary tract. Some of the more resistant strains of Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and Pseudomonas aeruginosa were studied in a dynamic in-vitro model in order to study dosing strategies. The model simulated, in Mueller-Hinton broth, the profile of plasma lomefloxacin concentrations in volunteers. Bacteria were exposed to a range of lomefloxacin concentration profiles achievable by oral dosing. The first dose of lomefloxacin was rapidly bactericidal in a dose-dependent manner for all strains. On re-exposure, a dose-dependent inhibitory effect was observed. Drug-resistant mutants were readily isolated from all bacteria tested on lomefloxacin-containing plates. These occurred at a high frequency in P. aeruginosa (10(-1)), but less frequently in K. pneumoniae (10(-3)). P. mirabilis (10(-5)), and E. coli (10(-6)). The number of resistant mutants isolated tended to be lower with use of higher drug concentrations. The results suggest that lomefloxacin dosing regimens ensuring maintenance of a high serum concentration: MIC ratio will result in maximal antibacterial effects and minimal problems with resistant strains.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856127     DOI: 10.1093/jac/27.4.481

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; G Cornaglia
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model.

Authors:  S B Duffull; E J Begg; S T Chambers; M L Barclay
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

4.  Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro.

Authors:  M L Barclay; E J Begg; S T Chambers; D R Boswell
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 5.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

6.  Adaptive resistance following single doses of gentamicin in a dynamic in vitro model.

Authors:  M L Barclay; E J Begg; S T Chambers
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.